Understanding Trulicity and Its Uses
Trulicity is a prescription medication designed to help adults manage type 2 diabetes. Containing the active ingredient dulaglutide, this biologic drug works alongside diet and exercise to improve blood sugar control. Additionally, it is prescribed to reduce the risk of major cardiovascular events, such as heart attacks or strokes, in adults who have type 2 diabetes and established heart disease or multiple cardiovascular risk factors.
How Trulicity Works in the Body
As a glucagon-like peptide-1 (GLP-1) receptor agonist, Trulicity mimics natural hormones in the body to regulate blood glucose. It stimulates the pancreas to release insulin when blood sugar levels are high, slows down gastric emptying to prevent post-meal spikes, and limits the liver from releasing excess sugar into the bloodstream. These combined mechanisms help maintain stable glycemic levels throughout the week.
Dosage and Administration Guidelines
Trulicity is administered as a subcutaneous injection once a week. It comes in prefilled, single-dose pens, making self-injection convenient. The typical starting dose is 0.75 mg weekly, which a healthcare provider may gradually increase up to a maximum of 4.5 mg based on individual blood sugar response. Injections can be administered in the abdomen, thigh, or upper arm, rotating the site with each dose.
Potential Side Effects and Risks
Common side effects associated with Trulicity are primarily gastrointestinal, including nausea, vomiting, diarrhea, abdominal pain, decreased appetite, and constipation. While these mild symptoms often subside within a few weeks, more serious risks can occur. These include pancreatitis, severe hypoglycemia when combined with other diabetes medications, kidney dysfunction, and gallbladder problems.
Important Precautions and Warnings
Trulicity carries a boxed warning regarding the potential risk of thyroid C-cell tumors. It should not be used by individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Patients should also discuss any history of diabetic retinopathy, pancreatitis, or severe gastrointestinal diseases like gastroparesis with their doctor before starting treatment.
Leave a Reply